Rayca Precision Molecular intelligence that reasons, computes and learns
Rayca turns molecular successes and failures into design principles that guide what to design, simulate and test next.
The attrition problem 01
Rayca converts failure modes into design principles that every future decision can use.
From failed molecule to missing design principle
Representative oncology programMolecular design question
What did every prior molecule prove this design must avoid?
Assays
Assay systems and LIMS
18,240 molecular outcomes
Chemistry
Registries and notebooks
3,120 synthesized compounds
Structures
Experimental and modelled
46 conformational records
Developability
ADME and safety reports
212 liability reports
Decisions
Reviews and meeting notes
390 program reviews
Scientific expertise
Distributed across teams
14 domain specialists
15 years
From target to approval
$2.6B
Cost per approved drug
90%
Of clinical candidates lost
Commonly cited industry estimates. Each cell is one clinical candidate.
The intelligence layer 02
This is how molecular intelligence becomes operational, and how it advances toward molecular superintelligence.
This is how molecular intelligence becomes operational, and how it advances toward molecular superintelligence.
The architecture of operating molecular intelligence
From evidence to agency- Sovereign by design. Your science and intelligence stay yours.
- Auditable at every decision. Evidence, methods and uncertainty remain exposed.
- More capable with every cycle. Every outcome expands what the system can reason about.
Layer 01 · Molecular world model
4,612 outcomes
A model of what happened, built to guide what happens next.
- Assays
- Chemistry
- Structures
- ADME
- Safety
- Notes
Lineage of one value
- RC-0512, PARP2 IC50
- Partner laboratory export
- Units and assay version reconciled
- Linked to structure, series and notes
Context preserved
Every outcome keeps its molecular context.
Failure made computable
Liabilities become reusable evidence.
Judgment carried forward
Institutional judgment carries forward.
Advances an expanding model of molecular possibility
Our approach 03
A molecule advances as one system, not as a sequence of disconnected scores.
One molecule. One integrated judgment
RC-0512- Medicinal chemistrySAR, synthetic tractability
- Structural biologyBinding mode, pocket states
- BiochemistryPARP1 and PARP2 potency
- DMPKSolubility, permeability, clearance
- SafetyhERG, blood counts
- TranslationalExposure at projected dose
3 vectors open
H-bond to Gly863
PARP1 1.2 nM
85 µM soluble
hERG > 30 µM
50 mg once daily
Molecular perception 01
The program becomes machine-readable.
Evidence entering the molecular world model
- Compound registry3,120 compounds
- PARP1 and PARP2 assays9,804 values
- Crystal structures12 files
- ADME panel418 results
- Rat safety study1 report
- Meeting notes64 documents
Principle formation 02
Failure becomes a design principle.
| PARP1 IC50 | PARP2 IC50 | Kinetic solubility | Caco-2 efflux | hERG | Rat blood counts | |
|---|---|---|---|---|---|---|
| RC-0412 | ||||||
| RC-0433 | ||||||
| RC-0451 | ||||||
| RC-0467 | ||||||
| RC-0480 | ||||||
| RC-0486 | ||||||
| RC-0490 | ||||||
| RC-0494 | ||||||
| RC-0497 | ||||||
| RC-0503 |
Each cell is one measured outcome. Red cells failed their target product profile threshold.
Failure mode
PARP2 activity
Tracks with the platelet and neutrophil drop in the 14-day rat study.
Design principle, now executable
PARP2 / PARP1 IC50 ratio of 100 or more
Seen in 5 compounds, backed by 22 measurements
Intelligence-guided design 03
The system creates within what the program has learned.
Olaparib, the reference chemotype
0 proposed, 0 pass every rule
Each cell is one generated molecule. Ink passed every constraint, red broke a learned constraint, grey scored below the potency model.
RC-0512
Cyanopyridine replaces the amide cap
- PARP2 window–
- cLogP below 3–
- No basic amine–
RC-0515
A nitrogen added to the core ring
- PARP2 window–
- cLogP below 3–
- No basic amine–
RC-0518
A spiro ring replaces the piperazine
- PARP2 window–
- cLogP below 3–
- No basic amine–
RC-0521
A basic amine on the piperazine
- PARP2 window–
- cLogP below 3–
- No basic amine–
Physical reasoning 04
Physics tests which designs deserve to be made.
- Ensemble docking9 compounds · CPU
- Molecular dynamics, 100 ns6 compounds · GPU
- RBFE, PARP13 compounds · GPU
- RBFE, PARP23 compounds · GPU
GPU fleet. Blue cells run this campaign.
Predicted PARP2 / PARP1 window
- RC-0512–
- RC-0518–
- RC-0515–
Line marks the 100-fold constraint.
Molecular action 05
Evidence becomes an executable next move.
Cycle 5 synthesis plan
- 01SynthesiseRC-0512 and RC-0518Pass every rule and are predicted to favour PARP1 by 140 to 180 times.
- 02Run firstPARP2 counter-screen and 7-day rat CBCConfirms the window in vitro and in vivo before scale-up.
- 03DeprioritiseRC-0515 and RC-0521One is not selective enough. One breaks the efflux rule.
Intelligence behind this action
4,612
records
3
constraints
9
simulations
1
partner assay
RC-0512 against the target product profile
- PARP1 IC50, predicted–
- PARP2 / PARP1 window–
- cLogP–
- Basic amine–
- Caco-2 efflux ratio, predicted–
Molecular intelligence, by cycle
C1
C2
C3
C4
C5
Lab results return to the program record and cycle 5 starts from there.
Representative program. Values are illustrative.
Lab in the loop 05
Every experiment becomes both an answer and new intelligence.
Where intelligence meets experiment
PARP2 cellular counter-screen1/5 Open question
- Question
- Does the PARP2 window hold in cells?
- Matched assay
- Cellular PARP2 counter-screen, partner catalogue
- Approval
- Approved by the project lead
- PARP2 IC50, RC-0512
- > 3 µM
- Molecular world model
- Selectivity principle updated for cycle 5
Darker wells show stronger PARP2 inhibition. Red marks a compound losing its window. Illustrative.
Where we differ 06
Options are abundant. Defensible molecular decisions compound.
Options are abundant. Defensible molecular decisions compound.
Failure becomes design intelligence
Every failed molecule leaves behind an evidence-linked principle that governs future designs.
- PARP2 window
- cLogP below 3
- No basic amine
Computation becomes agency
The system plans and supervises AI, simulation, GPU and HPC work within scientific and operational constraints.
RBFE campaign · 0 of 48 GPUs allocated
Every decision exposes its reasoning
Recommendations trace to the molecules, evidence, methods and uncertainty that produced them.
Scientists remain in command
Rayca expands the team’s capacity to reason and execute. Scientists retain every go and no-go decision.
Partnering 07
A focused scientific entry point into a much larger intelligence architecture.
A focused scientific entry point into a much larger intelligence architecture.
One program. One intelligence loop
One programDefine the decision
One program, one consequential question
Establish the world model
Evidence connected inside your environment
Run the intelligence loop
Principles, design, physics and compute
Return molecular action
Prioritized designs and experiments
Program intelligence
The hidden constraints, unresolved questions and next actions inside a running program.
Molecular second opinion
Independent reasoning before the next synthesis or IND-enabling commitment.
Failure-to-principle analysis
Past attrition converted into constraints the next design must respect.
Intelligence-guided design cycle
New matter designed, physically tested and prioritized with complete lineage.
What the intelligence loop returns
Molecular world model
Program evidence connected with provenance.
Executable design principles
Failure modes converted into future constraints.
Prioritized molecular actions
What to design, simulate and test next.
Reasoning for every decision
Evidence, methods and uncertainty exposed.
Advancing molecular intelligence with institutions at the scientific frontier.
Our collaborators connect molecular intelligence to frontier biology, translational science and therapeutic creation. Rayca is part of the DayOne Accelerator in Basel and Health Incubator Helsinki.
Therapeutic co-development partners
Accelerator and ecosystem partners
Vision 08
The destination is an intelligence capable of understanding and engineering molecular systems beyond the reach of any individual model, discipline or program.
The destination is an intelligence capable of understanding and engineering molecular systems beyond the reach of any individual model, discipline or program.
The path to molecular superintelligence
Our direction- L1ConnectedMolecular evidence becomes one traceable world model.Today
- L2Principle-formingSuccesses and failures become executable design knowledge.Today
- L3OperationalThe system reasons, designs and runs computation.Today
- L4ExperimentalIt proposes and coordinates experiments with scientific approval, then learns from reality.In development
- L5Molecular superintelligenceIt reasons from biological intent to development candidate across disciplines and modalities.Our direction